Cadrenal to begin tecarfarin trial in ESKD patients transitioning to dialysis later this year

Cadrenal Therapeutics, Inc.

Trial includes ESKD patients with and without atrial fibrillation, enrollment planned to begin later this year.
Tecarfarin has orphan drug and fast-track designations for ESKD+AFib, highlighting unmet need.
Addresses critical gap: no proven anticoagulant for dialysis initiation period, which carries excess cardiovascular risk.
CEO Quang X. Pham calls the study an important step forward for tecarfarin development.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.